Botulin Toxin Use in Scars/Keloids Treatment

Scala, Jacopo; Vojvodić, Aleksandra; Vojvodić, Petar; Vlaskovic-Jovicevic, Tatjana; Peric-Hajzler, Zorica; Matovic, Dusica; Dimitrijevic, Sanja; Vojvodić, Jovana; Sijan, Goran; Stepić, Nenad; Wollina, Uwe; Tirant, Michael; Thường, Nguyễn Văn; Fioranelli, Massimo; Lotti, Torello

doi:10.3889/oamjms.2019.783

Cited by 12 publications

(11 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The observations of sialidase activity with the RDE titration method showed that each isolate had various activity values. Overall, three isolates, B025, B048, and B060, had RDE titers of 2 4 ; four isolates, B023, B027, B033, and B055, had RDE titers of 2 5 ; and two isolates, B043 and B047, had RDE titers of 2 7 . B059 had an RDE titer of 2 6 , and the B028 code isolate had a higher titer than that of the other isolates with 2 8 dilutions of HI.…”

Section: Synthesis Of Sialidase and Determination Of C Perfringens Is...mentioning

confidence: 96%

See 1 more Smart Citation

Potency of bacterial sialidase Clostridium perfringens as antiviral of Newcastle disease infections using embryonated chicken egg in ovo model

et al. 2022

View full text Add to dashboard Cite

Background and Aim: Clostridium toxins are widely used as medicinal agents. Many active metabolic enzymes, including sialidase (neuraminidase), hyaluronidase, and collagenase, contribute to the mechanism of action of these toxins. Sialidase from Clostridium perfringens recognizes and degrades sialic acid receptors in the host cell glycoprotein, glycolipid, and polysaccharide complexes. Sialic acid promotes the adhesion of various pathogens, including viruses, under pathological conditions. This study aimed to investigate the potential of C. perfringens sialidase protein to inhibit Newcastle disease virus (NDV) infection in ovo model. Materials and Methods: C. perfringens was characterized by molecular identification through polymerase chain reaction (PCR) and is cultured in a broth medium to produce sialidase. In addition, sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis was conducted to characterize the sialidase protein. In contrast, enzymatic activity and protein concentration were carried out using a neuraminidase assay kit and Bradford to obtain suitable active substances. Furthermore, embryonated chicken egg models were used to observe the toxicity of several sialidase doses. Then, the hemagglutination (HA) titer was obtained, and absolute quantitative reverse transcription–PCR assay was performed to measure the viral replication inhibitory activity of sialidase against NDV. Results: Each isolate had a specific sialidase gene and its product. The sialidase derived from C. perfringens could hydrolyze the sialic acid receptor Neu5Ac (2,6)-Gal higher than Neu5Ac (2,3)Gal in chicken erythrocytes, as observed by enzyme-linked lectin assay. A significant difference (p = 0.05) in the HA titer in the pre-challenge administration group at dosages of 375 mU, 187.5 mU, and 93.75 mU in the competitive inhibition experiment suggests that sialidase inhibits NDV reproduction. Quantification of infective viral copy confirmed the interference of viral replication in the pre-challenge administration group, with a significant difference (p = 0.05) at the treatment doses of 750 mU, 375 mU, and 46.87 mU. Conclusion: The potency of sialidase obtained from C. perfringens was shown in this study, given its ability to reduce the viral titer and copy number in allantoic fluids without adversely impacting the toxicity of the chicken embryo at different concentrations.

show abstract

Section: Synthesis Of Sialidase and Determination Of C Perfringens Is...mentioning

confidence: 96%

“…Neurotoxins from Clostridium have been extensively studied in medical applications in the past 25 years. It has been used as a therapy for cases of muscle spasms and chronic pain and for cosmetic purposes [3,4].…”

Section: Introductionmentioning

confidence: 99%

Potency of bacterial sialidase Clostridium perfringens as antiviral of Newcastle disease infections using embryonated chicken egg in ovo model

et al. 2022

View full text Add to dashboard Cite

show abstract

“…BTA has been available for clinical use for more than 30 years and its efficacy and safety are well proved. Nowadays, an increasing number of studies have showed that BTA injections inhibit the formation of HS 2‐5 . Moreover, our previously published random clinical trial found that the injection of BTA in the early postoperative could decrease the scar formation, reduce the scar width, and make the overall appearance more satisfactory 6 .…”

Section: Introductionmentioning

confidence: 99%

Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF‐β1/Smad and ERK pathways

Yang

Zheng

et al. 2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background: Hypertrophic scar is a common complication in would healing process, and how to effectively prevent and treat it has been a hot and difficult research issue.Previous studies have showed that botulinum toxin type A (BTA) has effects on the prevention and treatment of hypertrophic scar, but little is known about the specific mechanisms.Objective: This study aimed to explore the potential mechanisms of BTA on the inhibition of hypertrophic scar formation.Methods: Hypertrophic scar-derived human fibroblasts were cultured and then treated with transforming growth factor-β1 (TGF-β1) and various concentrations of BTA. Cell proliferation and viability were measured by CellTiter 96® AQueous One Solution Cell Proliferation Assay and trypan blue staining, respectively. The total amount of collagen was examined using Sirius red staining. Collagen I and Collagen III in the culture supernatant were evaluated by enzyme-linked immunosorbent assay.Reverse transcription-quantitative polymerase chain reaction and Western blot analysis were performed to detect the transcription and translation levels.Results: Our results revealed that BTA decreased the proliferation of hypertrophic scar-derived human fibroblasts. The mRNA and protein expression levels of alphasmooth muscle actin, collagen I, and collagen III induced by TGF-β1 were inhibited by BTA in a dose-dependent manner. BTA also inhibited the phosphorylation of Smad2/3 and ERK. Conclusion:BTA decreased the proliferation of fibroblasts and prevented overdeposition of ECM through the inhibition of the TGF-β1/Smad and ERK pathways. The findings of this study provide new scientific reference for the prevention and treatment of hypertrophic scar.

show abstract

“…The clear mechanisms of action of BoNT-A in scar prevention and treatment are still not clearly understood; however, action on wound tension, collagen, and fibroblasts are proposed [15]. Moreover, it has shown that BoNT-A inhibits release of different substances like (TGF)-b, calcitonin gene-related peptide (CGRP), substance P, and glutamate, thus modulating cutaneous inflammation and wound healing [20].…”

Section: Discussionmentioning

confidence: 99%

Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study

et al. 2020

View full text Add to dashboard Cite

Background Scars are inevitable results of surgical procedures, and prevention of them is still a major problem in the field of cosmetic surgery. Although various studies have been performed on botulinum toxin-A (BoNT-A) injection for the prevention of hypertrophic scars, the exact mechanism remains unclear. Methods This prospective, double-blinded, randomized study was performed on 19 patients who underwent mammoplasty and abdominoplasty surgery in Razi Hospital from October 2018 to December 2019. Single session of treatment was performed, where XEOMIN was allocated to one half of the scar and 0.9% saline to the control half. 3 and 6 months later, scars were assessed using the modified Stony Brook Scar Evaluation Scale (SBSES). Results In total, 19 patients who completed the study were analyzed. mSBSES at the third month (P value \ 0.001; 3.34 ± 1.59 vs 1.5 ± 1.36) and the sixth month (P value \ 0.001; 4.89 ± 1.83 vs 2.39 ± 1.82) showed a significant difference between the treatment and control groups. In the subset analysis, there was significant difference between BoNT-A and control in all four items including width, height, color, and scar visibility at months 3 and 6, and the BoNT-A-treated sides had higher scores in all items. Conclusion BoNT-A has a significant effect on scar prevention due to mammoplasty and abdominoplasty compared to placebo and results in decreased erythema, height, width and reduces incision line visibility. Moreover, its effect increases significantly over time from months 3 to 6.

show abstract

Botulin Toxin Use in Scars/Keloids Treatment

Cited by 12 publications

References 33 publications

Potency of bacterial sialidase Clostridium perfringens as antiviral of Newcastle disease infections using embryonated chicken egg in ovo model

Potency of bacterial sialidase Clostridium perfringens as antiviral of Newcastle disease infections using embryonated chicken egg in ovo model

Botulinum toxin type A attenuates hypertrophic scar formation via the inhibition of TGF‐β1/Smad and ERK pathways

Botulinum Toxin Type A Injection for Mammoplasty and Abdominoplasty Scar Management: A Split-Scar Double-Blinded Randomized Controlled Study

Contact Info

Product

Resources

About